Choose an application

• Reference Manager
• EndNote
• RefWorks (Direct export to RefWorks)

Influenza continues to be an ongoing problem despite the existence of vaccines and drugs. Disease outbreaks can occur relatively quickly as witnessed with the recent emergence of the influenza virus A/H1N1 pandemic. The development of new anti-influenza drugs is thus a major challenge. This volume describes all aspects of the virus structure and function relevant to infection. The focus is on drug discovery of inhibitors to the enzyme sialidase, which plays a key role in the infectious lifecycle of the virus. Following an overview of the influenza virus, the haemagglutinin, the interactions with the cell receptors and the enzymology of virus sialidase, recent results in drug design are presented. These include a full coverage of the design, synthesis and evaluation of carbohydrate as well as non-carbohydrate influenza virus sialidase inhibitors. Further reviews of the clinical experience with influenza virus sialidase inhibitors and of the development of resistance to these inhibitor drugs complement the topic.

Tropical medicine. --- Influenza viruses --- Drug Discovery --- Respiratory Tract Infections --- Orthomyxoviridae Infections --- RNA Viruses --- Therapeutics --- Glycoside Hydrolases --- Investigative Techniques --- Chemistry, Pharmaceutical --- Vertebrate Viruses --- Analytical, Diagnostic and Therapeutic Techniques and Equipment --- Hydrolases --- Respiratory Tract Diseases --- Viruses --- RNA Virus Infections --- Diseases --- Chemistry --- Organisms --- Pharmacology --- Virus Diseases --- Enzymes --- Enzymes and Coenzymes --- Natural Science Disciplines --- Biological Science Disciplines --- Chemicals and Drugs --- Disciplines and Occupations --- Drug Therapy --- Orthomyxoviridae --- Drug Design --- Influenza, Human --- Neuraminidase --- Health & Biological Sciences --- Biology --- Pharmacy, Therapeutics, & Pharmacology --- Microbiology & Immunology --- Influenza viruses. --- Neuraminidase. --- Sialidase --- Medicine. --- Immunology. --- Pharmacology. --- Virology. --- Infectious diseases. --- Biomedicine. --- Pharmacology/Toxicology. --- Infectious Diseases. --- Glycosidases --- Orthomyxoviruses --- Toxicology. --- Emerging infectious diseases. --- Medical virology. --- Immunobiology --- Life sciences --- Serology --- Medical microbiology --- Virology --- Virus diseases --- Emerging infections --- New infectious diseases --- Re-emerging infectious diseases --- Reemerging infectious diseases --- Communicable diseases --- Chemicals --- Medicine --- Poisoning --- Poisons --- Toxicology --- Microbiology --- Drug effects --- Medical pharmacology --- Medical sciences --- Chemotherapy --- Drugs --- Pharmacy --- Physiological effect

Choose an application

• Reference Manager
• EndNote
• RefWorks (Direct export to RefWorks)

Skin inflammation is associated with a wide range of conditions which represent major health issues worldwide. Skin and mucosal surfaces represent the primary interface between the human body and the environment, susceptible to numerous factors whose action results in diseases produced by chemical substances, mechanical trauma, microbial agents, radiation, etc. Inflammation, a complex network of interactions between soluble molecules and cells, represents the main modality of the skin’s response to injuries. Numerous studies have revealed close links between chronic inflammation, oxidative stress, and carcinogenesis. Chronic inflammation induces the activation of various cell types and an increase in the production of reactive oxygen species, promoting the initiation of a malignant process. Identifying specific biomarkers is essential for understanding molecular mechanisms and developing therapies appropriate to the patient’s characteristics.Personalized medicine is an emerging field of medicine that has the potential to predict which therapy will be safe and efficacious for specific patients using an individual’s genetic profile to guide decisions regarding the diagnosis, treatment, as well as prevention of disease. This book gathers articles that present recent advancements in research involving the mechanisms that underlie the development of inflammatory skin disorders, skin and mucosal inflammation in general.

Medicine --- sea-buckthorn seed oil --- long-chain fatty acids --- skin dysplastic keratinocytes --- UVA --- CD36 --- SR-B2 --- atopic dermatitis --- eczema --- JAK inhibitors --- systematic review --- meta-analysis --- evidence-based medicine --- immune-mediated skin diseases --- target therapy --- skin conditions and systemic inflammatory diseases --- systemic sclerosis --- biomarker --- calumenin --- S100A6 --- cytohesin 2 --- cannabinoids --- inflammation --- gut-lung-skin barrier --- signaling pathways --- inflammatory biomarkers --- psoriasis vulgaris --- prevalence --- comorbidities --- risk factors --- systemic lupus erythematous --- lupus nephritis --- lipid peroxidation --- DNA oxidation --- oxidized proteins --- carbohydrate oxidation --- antioxidative stress strategies --- biomarkers --- IgY --- psoriatic dermatitis --- imiquimod --- C57 BL/6 mice --- alginate --- biomaterial --- dressing --- fibers --- hydrogel --- nanofibers --- commercially available --- wound care --- wound healing --- cutaneous melanoma --- epigenetic regulation --- drug resistance --- therapeutic targets --- epigenetic therapy --- immune response --- Sutton nevi --- halo nevi --- skin tumor --- psoriasis --- proteome analysis --- estrogen --- menopause --- cSCC --- AK --- sialylation --- sialyltransferase --- sialidase --- COVID-19 --- pyoderma gangrenosum --- immunosuppression --- cyclosporine --- corticosteroids --- autoinflammatory disease --- androgenic alopecia --- clinical trial --- hair density --- platelet-rich plasma --- sea-buckthorn seed oil --- long-chain fatty acids --- skin dysplastic keratinocytes --- UVA --- CD36 --- SR-B2 --- atopic dermatitis --- eczema --- JAK inhibitors --- systematic review --- meta-analysis --- evidence-based medicine --- immune-mediated skin diseases --- target therapy --- skin conditions and systemic inflammatory diseases --- systemic sclerosis --- biomarker --- calumenin --- S100A6 --- cytohesin 2 --- cannabinoids --- inflammation --- gut-lung-skin barrier --- signaling pathways --- inflammatory biomarkers --- psoriasis vulgaris --- prevalence --- comorbidities --- risk factors --- systemic lupus erythematous --- lupus nephritis --- lipid peroxidation --- DNA oxidation --- oxidized proteins --- carbohydrate oxidation --- antioxidative stress strategies --- biomarkers --- IgY --- psoriatic dermatitis --- imiquimod --- C57 BL/6 mice --- alginate --- biomaterial --- dressing --- fibers --- hydrogel --- nanofibers --- commercially available --- wound care --- wound healing --- cutaneous melanoma --- epigenetic regulation --- drug resistance --- therapeutic targets --- epigenetic therapy --- immune response --- Sutton nevi --- halo nevi --- skin tumor --- psoriasis --- proteome analysis --- estrogen --- menopause --- cSCC --- AK --- sialylation --- sialyltransferase --- sialidase --- COVID-19 --- pyoderma gangrenosum --- immunosuppression --- cyclosporine --- corticosteroids --- autoinflammatory disease --- androgenic alopecia --- clinical trial --- hair density --- platelet-rich plasma